Vontobel Holding Ltd. Purchases 159 Shares of United Therapeutics Corporation $UTHR

Vontobel Holding Ltd. lifted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 12.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,487 shares of the biotechnology company’s stock after purchasing an additional 159 shares during the period. Vontobel Holding Ltd.’s holdings in United Therapeutics were worth $427,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in UTHR. Farther Finance Advisors LLC grew its holdings in shares of United Therapeutics by 20.3% in the first quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 77 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of United Therapeutics by 22.7% in the first quarter. Fifth Third Bancorp now owns 487 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 90 shares during the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics in the first quarter valued at $49,000. Exchange Traded Concepts LLC boosted its holdings in United Therapeutics by 14.3% in the first quarter. Exchange Traded Concepts LLC now owns 4,643 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 581 shares in the last quarter. Finally, Great Lakes Retirement Inc. bought a new stake in United Therapeutics in the first quarter valued at $1,237,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.5%

Shares of UTHR stock opened at $433.61 on Wednesday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $459.48. The stock has a market cap of $19.56 billion, a PE ratio of 16.92, a price-to-earnings-growth ratio of 4.80 and a beta of 0.66. The company’s fifty day moving average price is $377.79 and its 200-day moving average price is $325.47.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the firm posted $5.85 EPS. The business’s quarterly revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday, September 10th. Bank of America lifted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a report on Wednesday, September 3rd. Royal Bank Of Canada initiated coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an “outperform” rating and a $569.00 price target on the stock. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $457.21.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 261,935 shares of company stock valued at $105,561,472. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.